Farmaceutica Remedia SA (RMAH) Stock Price, Fundamentals & Analysis

What RMAH does

Farmaceutica Remedia SA (symbol RMAH) operates a chain of pharmacies in Romania and is also active in the wholesale distribution of medicines to pharmacies, public and private hospitals, and clinics. In addition, the company provides packaging materials; and logistics and warehousing, promotion and marketing of drugs, and pharmaceutical products registration services. The company was incorporated in 1991 and is headquartered in Deva, Romania. It is part of the Healthcare sector on the Bucharest Stock Exchange (BVB) and operates in the Medical Distribution industry.

Key numbers explained

• The current price is 0.74 RON, with a 52-week range of 0.69 – 0.95 RON, showing the lowest and highest traded prices over the past year.
• The trailing P/E ratio of 18.4 indicates how much investors pay per RON of earnings; a higher number can suggest higher growth expectations or a richer valuation.
• The dividend yield of 6.76% reflects the annual dividend payment as a percentage of the current share price, making it a notable income feature.
• The ex-dividend date is 14 sept. 2026, the date by which you must own the stock to receive the upcoming dividend.
• 96% of earnings are paid out as dividends, meaning nearly all of the company's profit is returned to shareholders.
• The beta of 0.07 suggests the stock's price movements are historically much less volatile than the overall market.
• The price-to-book ratio of 0.86 means the stock trades below its book value per share, which can be interpreted as a potential valuation signal.
• The debt-to-equity ratio of 0.8% indicates the company's leverage level relative to shareholder equity.

Recent news

Recent headlines include the payment of the 2025 dividend, the release of the S1 2026 semi-annual report, and an investor and analyst conference call covering the S1/2026 results. Additional items reference the AGA E decisions dated 26.08.2026 and the availability of the Semestrul 1 2026 report.

What to watch

Investors in Farmaceutica Remedia SA typically monitor pharmacy sector competition, changes in medicine pricing and reimbursement policies, and the company's ability to grow its retail and wholesale network. Regulatory developments in the Romanian healthcare system and broader economic conditions that affect consumer spending on healthcare are also relevant factors. Peer companies such as Med Life S.A. (M), Antibiotice S.A. (ATB), Ropharma SA (RPH), and Biofarm S.A. (BIO) can provide useful context for comparison.